ABIOMED (ABMD) in Focus: Stock Surges 18% in Session - Tale of the Tape
ABIOMED, Inc. (ABMD) was a big mover last session, as the company saw its shares rise 18% on the day. The stock moved up after the U.S. Food and Drug Administration approved its heart pump Impella 2.5 for use during both elective and urgent high risk angioplasty procedures. This led to solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading above the near flat price range of $58.70–$62.19 over the past one-month time frame.
None of the estimates for this medical instruments industry stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
ABIOMED sports a Zacks Rank #1 (Strong Buy), while its Earnings ESP is negative.
Investors interested in the space can also consider Inogen, Inc. (INGN), also carrying a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABIOMED INC (ABMD): Free Stock Analysis Report
INOGEN INC (INGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
